Efficacy News and Research

RSS

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

Disulfiram was the first medication approved for the treatment of alcoholism over 50 years ago. It works, at least in part, by preventing the metabolism of an alcohol by-product, acetaldehyde. High levels of acetaldehyde in the body quickly cause unpleasant symptoms, including nausea, vomiting, headache, and accelerated heart rate. Thus, disulfiram provides a very strong incentive to avoid drinking.

1 Feb 2013

Span-America first quarter net income increases 21% to $1.4 million

Span-America Medical Systems, Inc. today reported higher sales and net income for the first quarter ended December 29, 2012.

31 Jan 2013

Top-line results from Vanda's tasimelteon Phase IIb/III study on major depressive disorder

Vanda Pharmaceuticals Inc. today announced top-line results of the Phase IIb/III clinical study (MAGELLAN) in Major Depressive Disorder (MDD), investigating the efficacy and safety of tasimelteon as a monotherapy in the treatment of patients with MDD.

31 Jan 2013

Velomedix commences rapid therapeutic hypothermia system pilot study in heart attack

Velomedix, a venture-backed medical device company advancing the field of therapeutic hypothermia, today announced the enrollment of the first patient in its VELOCITY pilot study.

31 Jan 2013

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.

31 Jan 2013

DSMB recommends continuation of CTI’s OPAXIO Phase 3 trial on ovarian cancer

Cell Therapeutics, Inc. (CTI) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIOTM (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis.

31 Jan 2013

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech, a member of the Roche Group, today announced positive results from Stage 1 of CLL11, a Phase III randomized study to investigate the efficacy and safety profile of the investigational medicine obinutuzumab (GA101) plus chlorambucil chemotherapy compared with chlorambucil alone in people with previously untreated chronic lymphocytic leukemia (CLL).

31 Jan 2013

Mount Sinai to initiate immunological therapy trial against chronic pulmonary sarcoidosis

Patients are currently being enrolled in the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis. The trial is being conducted by researchers at the Icahn School of Medicine at Mount Sinai.

31 Jan 2013

Pediatric migraine drugs show limited or no efficacy

There is limited evidence supporting the efficacy of trazodone and topiramate in the prevention of pediatric episodic migraine headaches, show results from a meta-analysis.

30 Jan 2013

Dilaforette receives approval to initiate sevuparin Phase II malaria study in India

Dilaforette, a Karolinska Development portfolio company, today announces that the company has approval from the regulatory authority in India to start a Phase II study with sevuparin in patients with moderate to severe malaria.

30 Jan 2013

Low-income and minority parents/guardians receptive toward vaccinating boys against HPV

A new Boston University School of Medicine (BUSM) study has found that low-income and minority parents/guardians were receptive toward vaccinating boys against Human Papilloma Virus (HPV). However, racial/ethnic differences emerged in attitudes regarding school-entry mandates. The findings appear online in the journal Clinical Pediatrics.

30 Jan 2013

Hyperbaric oxygen treatment new player in stroke rehabilitation

Treatment with hyperbaric oxygen therapy can lead to significant neurologic improvements for stroke patients, show study results.

29 Jan 2013

Viewpoints: Debating P4P; ‘Tactical retreat' by GOP; The virtues of across-the-board spending cuts

Instead of granting automatic pay increases, N.Y. City's public hospital system will pay them based on how well they reduce costs, increase patient satisfaction and improve the quality of care. The Health and Hospitals Corporation, which runs the city's 11 public hospitals, deserves praise for an ambitious proposal that will need to be refined as it is put into practice.

28 Jan 2013

Quantitative MRIs evade multiple sclerosis clinicoradiologic paradox

Quantitative magnetic resonance imaging can detect microstructural changes in the spinal cords of patients with multiple sclerosis that correlate with observed differences in clinical disability, according to a cross-sectional study in Neurology.

28 Jan 2013

Lumpectomy plus radiation may provide better chance of survival than mastectomy in early breast cancer patients

A new analysis has found that lumpectomy plus radiation for early breast cancer may provide patients with a better chance of survival than mastectomy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results provide confidence in the efficacy of breast-conserving treatments even among patients with aggressive, early disease.

28 Jan 2013

Post-traumatic stress disorder (PTSD) in children: an interview with Donna Gillies

Children with PTSD suffer significant distress or negative impacts on their daily lives. Estimates of the prevalence of PTSD in children and adolescents experiencing trauma are generally very high, at 30% to 40%.

28 Jan 2013

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

The U. S. Patent and Trademark Office recently issued a patent to the U. S. Department of Health and Human Services involving resiniferatoxin, or RTX, an experimental compound that represents a potential new class of drugs to alleviate the intractable pain that can occur in people with advanced cancer, severe arthritis, and other extremely chronic conditions.

28 Jan 2013

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.

28 Jan 2013

FDA accepts Genzyme’s LEMTRADA sBLA for review

Genzyme, a Sanofi Company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental Biologics License Application (sBLA) file seeking approval of LEMTRADA (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS).

28 Jan 2013

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the U.S. National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.

28 Jan 2013

Efficacy News and Research

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

Span-America first quarter net income increases 21% to $1.4 million

Top-line results from Vanda's tasimelteon Phase IIb/III study on major depressive disorder

Velomedix commences rapid therapeutic hypothermia system pilot study in heart attack

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

DSMB recommends continuation of CTI’s OPAXIO Phase 3 trial on ovarian cancer

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Mount Sinai to initiate immunological therapy trial against chronic pulmonary sarcoidosis

Pediatric migraine drugs show limited or no efficacy

Dilaforette receives approval to initiate sevuparin Phase II malaria study in India

Low-income and minority parents/guardians receptive toward vaccinating boys against HPV

Hyperbaric oxygen treatment new player in stroke rehabilitation

Viewpoints: Debating P4P; ‘Tactical retreat' by GOP; The virtues of across-the-board spending cuts

Quantitative MRIs evade multiple sclerosis clinicoradiologic paradox

Lumpectomy plus radiation may provide better chance of survival than mastectomy in early breast cancer patients

Post-traumatic stress disorder (PTSD) in children: an interview with Donna Gillies

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

FDA accepts Genzyme’s LEMTRADA sBLA for review

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News